DexCom (NasdaqGS:DXCM) has begun a broad U.S. rollout of its G7 15-day continuous glucose monitoring system, extending sensor wear time for users. The company is preparing a nationwide release of ...

アメリカ発データ活用のプロフェッショナル、ガーミンジャパン株式会社(以下 Garmin)は、Dexcomのアプリと連携して、Garminデバイスでのグルコース値データの表示を可能にしました。外部アプリやウォッチフェイス、データ項目などをGarminデバイスに ...

Q4 2025 Management View Jacob Leach, President, CEO & Director, marked his first call as CEO by outlining three strategic priorities: "We will be the premier glucose sensing solution for all," ...

テルモ、持続グルコースモニタシステム「Dexcom G6 CGMシステム」の使用目的又は効果が変更 リアルタイム持続グルコースモニタシステムとしては初めて血糖自己測定の併用が原則不要に テルモ株式会社（本社:東京都渋谷区、社長:佐藤 慎次郎）は、5月10日付 ...

DexCom, Inc. (NASDAQ:DXCM) is one of the 10 best healthcare equipment stocks to buy according to hedge funds. On February 13, William Plovanic from Canaccord Genuity reduced the price target on DexCom ...

Stifel projected that the 15-day sensor could enhance DexCom’s gross margin in 2026, potentially contributing to year-over-year EBITDA margin expansion. The firm acknowledged certain risks, including ...

DexCom DXCM recently announced that it has received FDA clearance for its CGM-integrated basal insulin dosing optimizer, Dexcom Smart Basal, for use by adults with Type 2 diabetes on glargine U-100 ...

Analysts expect DexCom to report earnings of $0.6459 per share on revenue of $1.24 billion for the quarter ended December 2025. That would mark a sequential improvement from the third quarter’s $0.61 ...